BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24716840)

  • 1. MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen.
    Tengström M; Mannermaa A; Kosma VM; Soini Y; Hirvonen A; Kataja V
    Acta Oncol; 2014 Jun; 53(6):769-75. PubMed ID: 24716840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
    Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
    Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?
    Tengström M; Mannermaa A; Kosma VM; Hirvonen A; Kataja V
    BMC Cancer; 2012 Jun; 12():257. PubMed ID: 22708928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in GSTM1 and XPD genes predict clinical outcome in advanced oral cancer patients treated with postoperative radiotherapy.
    Mahimkar MB; Samant TA; Kannan S; Tulsulkar J; Pai PS; Anantharaman D
    Mol Carcinog; 2012 Oct; 51 Suppl 1():E94-103. PubMed ID: 22213390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
    Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
    Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
    Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Polymorphism Lys751Gln of XPD gene and breast cancer risk in women].
    Romanowicz-Makowska H; Smolarz B
    Pol Merkur Lekarski; 2007 Aug; 23(134):107-9. PubMed ID: 18044339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.
    Kim HS; Yom CK; Kim HJ; Lee JW; Sohn JH; Kim JH; Park YL; Ahn SH
    Breast Cancer Res Treat; 2010 Jun; 121(3):777-88. PubMed ID: 19806450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer.
    Bewick MA; Conlon MS; Lafrenie RM
    Breast Cancer Res Treat; 2008 Sep; 111(1):93-101. PubMed ID: 17922231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
    Park IH; Ro J; Park S; Lim HS; Lee KS; Kang HS; Jung SY; Lee S
    Breast Cancer Res Treat; 2012 Jan; 131(2):455-61. PubMed ID: 21437611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of XRCC1/XPD/ERCC1 Polymorphisms in Predicting Prognosis of Hepatocellular Carcinoma in Patients Receiving Transcatheter Arterial Chemoembolization.
    Wang XC; Wang F; Quan QQ
    Genet Test Mol Biomarkers; 2016 Apr; 20(4):176-84. PubMed ID: 26918371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
    Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
    J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XRCC1 and XPD genetic polymorphisms, smoking and breast cancer risk in a Finnish case-control study.
    Metsola K; Kataja V; Sillanpää P; Siivola P; Heikinheimo L; Eskelinen M; Kosma VM; Uusitupa M; Hirvonen A
    Breast Cancer Res; 2005; 7(6):R987-97. PubMed ID: 16280050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
    Mo J; Luo M; Cui J; Zhou S
    Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese.
    Kiyotani K; Mushiroda T; Tsunoda T; Morizono T; Hosono N; Kubo M; Tanigawara Y; Imamura CK; Flockhart DA; Aki F; Hirata K; Takatsuka Y; Okazaki M; Ohsumi S; Yamakawa T; Sasa M; Nakamura Y; Zembutsu H
    Hum Mol Genet; 2012 Apr; 21(7):1665-72. PubMed ID: 22180457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
    Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
    Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.
    Abraham JE; Maranian MJ; Driver KE; Platte R; Kalmyrzaev B; Baynes C; Luccarini C; Shah M; Ingle S; Greenberg D; Earl HM; Dunning AM; Pharoah PD; Caldas C
    Breast Cancer Res; 2010; 12(4):R64. PubMed ID: 20731819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.